CCC Diagnostics has received expand insurance coverage for the DirectHit Test Panel for Breast Cancer. This expanded coverage includes Medicare, CareFirst BlueCross/Blue Shield, WellPoint Unicare Networks, CMS Highmark Medicare Services and AmeriGroup DirectHit allows physicians to personalize the treatment of breast cancer patients.
CCC Diagnostics, Inc (CCCD), announced today that the Centers for Medicare & Medicaid will provide coverage for their Drug Response Indicator Test tra ...
CCC Diagnostics Inc has been awarded a Qualifying Therapeutic
Discovery grant for the DirectHit Test Panel for Breast Cancer. The
funding will allow the company to expand the offerings of the DirectHit test, which is designed to accurately predict the tumor's response to commonly prescribed classes of anti-cancer drugs.
CCC Diagnostics, Inc. has received a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the ...
CCC Diagnostics has introduced the DirectHit Test Panel for Breast Cancer. This test predicts the response to drugs used in the treatment of breast cancer. DirectHit allows physicians to personalize treatments for breast cancer patients.
Baltimore, MD - CCC Diagnostics, Inc., headquartered in Baltimore, Maryland, announced today that it has launched the DirectHitTM Test Panel for Breas ...
Satisfied Users & 
Approved Press Releases
